Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Dasatinib vs imatinib in the treatment of paediatric ALL

Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )
24 Dec 2019

Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
24 Dec 2019

PET-Directed therapy for early-stage diffuse large B-cell lymphoma

Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA
PET-Directed therapy for early-stage diffuse large B-cell lymphoma ( Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA )
24 Dec 2019

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
24 Dec 2019

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans

Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )
19 Dec 2019

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
19 Dec 2019

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )
19 Dec 2019

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel

Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA
Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel ( Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA )
19 Dec 2019

Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14

Prof Anthony Moorman - Newcastle University, Newcastle, UK
Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14 ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
19 Dec 2019

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer

Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )
19 Dec 2019

The challenges of treating breast cancer in Brazil

Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
The challenges of treating breast cancer in Brazil ( Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil )
19 Dec 2019

The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC

Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany
The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )
19 Dec 2019